Parthenon

Parthenon Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of PRTH-101, a Novel DDR1 Inhibitor for the Treatment of Immune-Excluded Solid Tumors

Retrieved on: 
Tuesday, April 25, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, DDR1, Cancer, Neoplasm, FDA, Therapy, MD, Tumor microenvironment, Patient, Parthenon, TME, Medical imaging

Parthenon Therapeutics , a precision oncology company discovering and developing a novel class of therapies that reprogram the tumor microenvironment (TME), today announced that the first patient has been dosed with PRTH-101 in a Phase 1, first-in-human clinical trial for patients with immune-excluded solid tumors.

Key Points: 
  • Parthenon Therapeutics , a precision oncology company discovering and developing a novel class of therapies that reprogram the tumor microenvironment (TME), today announced that the first patient has been dosed with PRTH-101 in a Phase 1, first-in-human clinical trial for patients with immune-excluded solid tumors.
  • PRTH-101 is a first-in-class Discoidin Domain Receptor 1 (DDR1) antagonist monoclonal antibody that is expressed at very high levels in solid tumors with low levels of T cell infiltration.
  • PRTH-101 is the first development candidate from Parthenon’s broad TME-focused pipeline to enter clinical development.
  • PRTH-101 uniquely targets DDR1 and has demonstrated, in preclinical models, anti-tumor activity as a single agent and in combination with an anti-PD-1 checkpoint inhibitor.

Parthenon Therapeutics Announces Data at the American Association for Cancer Research (AACR) Annual Meeting 2023 on Prevalence of Immune Exclusion in Solid Tumors to Support Phase 1 Clinical Trial of PRTH-101

Retrieved on: 
Monday, April 17, 2023
Oncology, Health, FDA, Clinical Trials, Research, Science, AACR, Prevalence, DDR1, Clinical trial, Clinical research, Cancer, Multimedia, Lung cancer, Doctor of Philosophy, Parthenon, Incidence, Sarcoma, Translational medicine, Patient, Colorectal cancer, TME, Immunohistochemistry, American Association for Cancer Research, Therapy, Ovarian cancer, Tumor microenvironment, Pharmaceutical industry, Vaccine, MD

The data further support Parthenon’s planned Phase 1 clinical trial of lead candidate PRTH-101, a novel Discoidin Domain Receptor (DDR1) inhibitor which targets DDR1-directed collagen barriers in immune excluded tumors.

Key Points: 
  • The data further support Parthenon’s planned Phase 1 clinical trial of lead candidate PRTH-101, a novel Discoidin Domain Receptor (DDR1) inhibitor which targets DDR1-directed collagen barriers in immune excluded tumors.
  • However, most patients with solid tumors lack immune cells in physical proximity to tumor cells.
  • This can be due to collagen barriers that prevent immune cells from reaching tumor cells in immune excluded tumors.
  • The poster detailing these findings - #2108 - will be presented at the American Association of Cancer Research (AACR) Annual Meeting on Monday, April 17, 2023.

loanDepot Announces Settlement and Cooperation Agreement with Anthony Hsieh

Retrieved on: 
Wednesday, April 5, 2023
Size, PAM, Annual Meetings of the International Monetary Fund and the World Bank Group, Annual general meeting, Vision 2025, LDI, LoanDepot, NYSE, Company secretary, Holding company, Management, Parthenon

IRVINE, Calif., April 4, 2023 /PRNewswire/ -- loanDepot, Inc. ("loandepot," "LDI" or the "Company") (NYSE: LDI) today announced that it has entered into a settlement and cooperation agreement with Anthony Hsieh, LDI's Chairman of the Board, founder and largest shareholder. Pursuant to the agreement, the size of the Company's Board of Directors will be temporarily increased from eight to nine directors and Steven Ozonian will join the Board immediately. Ozonian, along with current directors Andrew Dodson and Pamela Hughes Patenaude, will be nominated for election to three-year terms at the 2023 Annual Meeting.

Key Points: 
  • Board Size to be Temporarily Increased from Eight to Nine Directors, with Steven Ozonian Joining the Board Immediately
    IRVINE, Calif., April 4, 2023 /PRNewswire/ -- loanDepot, Inc. ("loandepot," "LDI" or the "Company") (NYSE: LDI) today announced that it has entered into a settlement and cooperation agreement with Anthony Hsieh, LDI's Chairman of the Board, founder and largest shareholder.
  • "We believe that reaching this agreement with Anthony is clearly in the best interests of loanDepot and all of its shareholders," said Dawn Lepore, Chair of the Board's Nominating and Corporate Governance Committee.
  • The size of the Board will return to eight directors effective as of the 2024 Annual Meeting, subject to the terms of the cooperation agreement.
  • The agreement will be filed with the U.S. Securities and Exchange Commission as an exhibit to a Current Report on Form 8K.

Parthenon Capital Announces Closing of Parthenon Investors VII

Retrieved on: 
Monday, March 27, 2023
Finance, Data Analytics, Professional Services, Asset Management, Insurance, Capital, Documentation, Ropes & Gray, Kirkland & Ellis, Parthenon

Parthenon Capital, a leading growth-oriented private equity firm with offices in Boston, San Francisco and Austin, announced its affiliate, Parthenon Investors VII (“Parthenon Fund VII”), held its first and final closing with more than $4.5 billion in commitments.

Key Points: 
  • Parthenon Capital, a leading growth-oriented private equity firm with offices in Boston, San Francisco and Austin, announced its affiliate, Parthenon Investors VII (“Parthenon Fund VII”), held its first and final closing with more than $4.5 billion in commitments.
  • Parthenon Fund VII exceeded its initial fund target of $3.5 billion.
  • “We appreciate the swift, significant support we received from existing limited partners and are excited to welcome an outstanding group of new investors to the Parthenon family,” said Brian Golson, managing partner and co-chief executive officer.
  • Parthenon did not use a placement agent in the fundraising.

Parthenon Capital Announces Transition of Gaming Division of Global Payments to Pavilion Payments

Retrieved on: 
Monday, February 13, 2023
Software, Finance, Banking, Professional Services, Technology, Electronic Games, Fintech, Entertainment, Justice, Wachtell, Lipton, Rosen & Katz, Global Payments, NYSE, DLA Piper, Capital, Cayan, Ecosystem, Kirkland & Ellis, Greenhill & Co., VIP, Partnership, GPN, Financial services, Sales, Cryptocurrency, Parthenon

Parthenon Capital (“Parthenon”), a leading growth-oriented private equity firm, announced they have entered into a definitive agreement with Global Payments Inc. (NYSE: GPN) to acquire its gaming division and transition Global Payments Gaming Solutions into Pavilion Payments, a stand-alone independent company.

Key Points: 
  • Parthenon Capital (“Parthenon”), a leading growth-oriented private equity firm, announced they have entered into a definitive agreement with Global Payments Inc. (NYSE: GPN) to acquire its gaming division and transition Global Payments Gaming Solutions into Pavilion Payments, a stand-alone independent company.
  • After closing on the transaction, Pavilion Payments will continue to offer Global Payments Gaming Solutions’ full suite of payments solutions for the gaming industry, including VIP Preferred and the award-winning cashless solution VIP Mobility.
  • Pavilion Payments will deliver the world’s most innovative integrated payments ecosystem, enabling gaming operators to create seamless consumer experiences across their physical and digital properties.
  • Evercore is serving as exclusive financial advisor and Wachtell, Lipton, Rosen & Katz is serving as legal advisor to Global Payments.

Holland America Line's 'Kids Cruise Free' Offer Extension Makes NOW the Time to Book a Family Vacation

Retrieved on: 
Friday, February 17, 2023
Peggy, Life, HAL, Peggy's Cove, Nova Scotia, Holland America Line, Mac, Parthenon, Ship, System, Gold, Time of Your Life, Museum, Acadia National Park, Travel, Cheese, Panama Canal, Nature, Meal, Friends, Culture, Sport, Vasa, Family, America Line, Nile, Sphinx, Architecture, US, Drink, Pyramid, Wi-Fi, Ageing, Hotel, Tourism, Baltic, Club

SEATTLE, Feb. 17, 2023 /PRNewswire/ -- Travelers looking to book a memorable family getaway can take advantage of Holland America Line's "Time of Your Life" wave season promotion that includes a kids cruise free perk. This is in addition to receiving a free stateroom upgrade, fare discounts and reduced deposits -- plus tours, beverages, specialty dining and Wi-Fi when booking the "Have It All" premium package.

Key Points: 
  • Whether it's a family that loves to travel the world or one that's looking to stay closer to home, Holland America Line is including a variety of destinations with the kids cruise free offer.
  • Families can book a sailing to Alaska, Canada/New England, Europe, the Caribbean, Mexico, Pacific Coast and through the famed Panama Canal.
  • One of the most sought-after family vacations is a cruise to Alaska , and no one explores The Last Frontier like Holland America Line.
  • For more information about Holland America Line, consult a travel advisor, call 1-877-SAIL HAL (877-724-5425) or visit hollandamerica.com .

K1 Speed Opens Nashville Go Karting Center With IndyCar Champion Will Power

Retrieved on: 
Thursday, February 16, 2023
Will Power, IndyCar, Drink, Indy, Kart racing, Nissan Stadium, Food, Culture, Parthenon, F1, Ryman Auditorium, Partnership, Amusement park

IRVINE, Calif., Feb. 16, 2023 /PRNewswire/ -- K1 Speed, the world's largest indoor go kart racing operator, is thrilled to announce today the opening of K1 Speed Nashville by Will Power!

Key Points: 
  • IRVINE, Calif., Feb. 16, 2023 /PRNewswire/ -- K1 Speed, the world's largest indoor go kart racing operator, is thrilled to announce today the opening of K1 Speed Nashville by Will Power!
  • K1 Speed Nashville by Will Power will feature everything that millions of guests have enjoyed since the company's founding in 2003.
  • Will Power, partner of K1 Speed Nashville, is one of the greatest IndyCar drivers to have ever raced.
  • I still race karts to this day, so I'm extremely excited to bring K1 Speed to Nashville."

Normunity Appoints Olga Granaturova as Chief Operating Officer and Chief Business Officer

Retrieved on: 
Thursday, January 19, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, R, Pharmacy, Merck, Therapy, Entrepreneurship, Parthenon, MD, London, Evotec, Woman, HEC Paris, SUNY, Growth, BS, Drug discovery, Cancer, New York University Stern School of Business, Pfizer, MBA, Multimedia, Paris, London School of Business and Finance, Pharmaceutical industry, Economics, Buffalo

Normunity, Inc ., a biotechnology company creating novel precision anti-cancer immunotherapies, today announced the appointment of Olga Granaturova, MBA, as Chief Operating Officer and Chief Business Officer.

Key Points: 
  • Normunity, Inc ., a biotechnology company creating novel precision anti-cancer immunotherapies, today announced the appointment of Olga Granaturova, MBA, as Chief Operating Officer and Chief Business Officer.
  • View the full release here: https://www.businesswire.com/news/home/20230119005216/en/
    Normunity COO-CBO Olga Granaturova (Photo: Business Wire)
    “We are delighted to welcome Olga to the Normunity Leadership Team.
  • Her hands-on experience in business creation, financing and business development will play a vital role as we continue to grow,” said Rachel Humphrey, MD, founding Chief Executive Officer of Normunity.
  • She joins Normunity after serving as co-founder and Chief Operating Officer of Parthenon Therapeutics, a biotech company creating a novel class of anti-cancer therapies.

Parthenon Therapeutics Appoints Joseph Paul Eder, MD, as Chief Medical Officer

Retrieved on: 
Thursday, December 15, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Therapy, Yale School of Medicine, Georgetown University School of Medicine, Associate professor, Yale school, Pharmacology, TME, Patient, Clinical research center, Cancer, Experiment, Research, Precision medicine, Assistant professor, Yale University, AstraZeneca, Drug resistance, Drug development, Medicine, PLC, Tumor microenvironment, Science, Growth, Harvard Medical School, Dana–Farber Cancer Institute, Neoplasm, Pharmaceutical industry, Oncology, Hematology, MD, Parthenon

Parthenon Therapeutics, a biotech company inventing a novel class of anti-cancer therapies that reprogram the tumor microenvironment (TME), today announced the appointment of Joseph Paul Eder, MD, as Chief Medical Officer.

Key Points: 
  • Parthenon Therapeutics, a biotech company inventing a novel class of anti-cancer therapies that reprogram the tumor microenvironment (TME), today announced the appointment of Joseph Paul Eder, MD, as Chief Medical Officer.
  • We are excited to welcome Dr. Joseph Paul Eder to Parthenon as Chief Medical Officer.
  • His experience also extends to the pharmaceutical industry where he was Senior Medical Science Director & Global Clinical Medical Director, Hematology at AstraZeneca, PLC.
  • Dr. Eder is Chief Medical Officer at Parthenon, bringing over 30 years of clinical experience at leading cancer research institutions as well as the pharmaceutical industry.

Reservations Now Open for Growing 2024 Calendar of Four Seasons Private Jet Journeys

Retrieved on: 
Tuesday, December 13, 2022
Titan, Atlas Mountains, Heart, Airbus, UNESCO, Machu Picchu, Visa, Riviera, Burj Khalifa, World Heritage Site, Erik Hassle, Arnold Palmer, Titan Airways, Friends, City, Chessington World of Adventures, Aircraft, Great Barrier Reef, Snorkeling, Calendar, Crystal Island: Uncharted Discovery, Martini, Parthenon, Port Jackson, Hand, Uncharted, Business, Vespa, Travel, Four Seasons, Atmosphere, Global health, TCS, Collection, News, Pyramid, Daintree Rainforest, Hotel, Tourism, Animal, Amusement park, Airline, Season, Casino Royale, Pacific Ocean, Antarctica, Bögöt

TORONTO, Dec. 13, 2022 /PRNewswire/ -- Leading luxury company Four Seasons reveals the next set of Four Seasons Private Jet Experiences for 2024, featuring a collection of extraordinary journeys to far-reaching destinations across the globe, all in the comfort and care of Four Seasons on the ground, and in the air.  

Key Points: 
  • As always, accommodations on Four Seasons Private Jet Experiences are at Four Seasons hotels and resorts.
  • In addition to four journeys already announced for 2024 Four Seasons continues to add to the calendar with the return of three popular trips later in the year.
  • For more information on how to book a one-of-a-kind global adventure aboard the custom-designed Four Seasons Private Jet, click here .
  • All Four Seasons Private Jet Experiences adhere to the company's recently expanded global health and safety program, Lead With Care.